通讯作者: 邵蓉, shaorong116@163.com

DOI：10.12201/bmr.202409.00048

The Inspiration of the Design of Drug Medical Insurance Payment Standard System in typical countries and regions for China——From the perspective of original drug management

• 摘要：目的 为国家药品集中采购政策背景下的药品医保支付标准管理提供参考。方法 通过对典型国家和地区的药品医保支付标准管理经验进行研究。结果 研究的典型国家和地区具有较为完备的药品医保支付标准管理体系，参考市场实际交易价格等多重因素，仿制药与原研药医保支付标准存在差异。结论 建议完善相关政策文件，建立科学的药品医保支付标准管理体系，通过药品市场价格交易监测机制，构建以市场为导向的医保支付标准形成机制，根据仿制药与原研药等不同药品的不同属性进行精细化分类管理；同时，在当前国家药品集中采购品种同通用名实行同一医保支付标准的政策前提下，建议继续推进并优化仿制药一致性评价工作，实现仿制药与原研药临床疗效一致，以符合当前仿制药与原研药实行同一医保支付标准的政策导向。

  关键词： 国家药品集中采购; 医保支付标准; 原研药; 药品价格

   

  Abstract: OBJECTIVE To provide reference for the management of drug medical insurance payment standard under the background of the national drug centralized procurement policy. METHOD Research on the management experience of drug and medical insurance payment standard in typical countries and regions. RESULT There is a relatively complete drug medical insurance payment standard management system in the typical countries and regions of studied, refer to multiple factors such as the actual trading price in the market，and there are differences in drug medical insurance payment standard between generic and original drug. CONCLUSION It is recommended to improve relevant policy documents, and establish a scientific management system for drug medical insurance payment standards, establish a market-oriented mechanism for forming drug medical insurance payment standards through drug market price transactions, and refine classification management based on different attributes of different drugs such as generic drugs and original drugs；At the same time, under the current policy of implementing the same drug medical insurance payment standard for drugs with the same generic name of national drug centralized procurement, it is recommended to continue promoting and optimizing the consistency evaluation of generic drugs, achieving consistency in clinical efficacy between generic drugs and original drugs, in line with the current policy orientation of implementing the same drug medical insurance payment standard for generic drugs and original drugs.

  Key words: National Centralized Drug Procurement; Medical Insurance Payment Standard; Original Drug; Drug Price

  提交时间：2024-09-23

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 孙文俊, 赵子寅, 成哲玉, 李慧宁, 祝贺. 药品集中采购政策对药品价格和使用影响的系统综述. 2023. doi: 10.12201/bmr.202303.00033

  王彪, 张天天, 唐啸宇, 贾韵, 罗力. 国家组织药品带量采购政策的降价持续性研究. 2023. doi: 10.12201/bmr.202305.00008

  孙言, 朱正, 杨莉. 国家组织药品集中带量采购价格降幅影响因素分析. 2022. doi: 10.12201/bmr.202203.00008

  王彪, 张天天, 唐啸宇, 贾韵, 罗力. 我国集中带量采购中选药品价格的差异及区域分布研究. 2023. doi: 10.12201/bmr.202306.00008

  唐玉清, 李胤铭, 陈西卓, 薛天琴, 陈昊. 基于政策执行系统模型的药品集中采购政策执行分析. 2023. doi: 10.12201/bmr.202310.00002

  李钊, 赵珂, 周绿林, 陈盛. 国家集采常态化视域下药品集团采购模式对比及发展对策研究. 2021. doi: 10.12201/bmr.202109.00037

  韩欣茹, 曾康妮, 谭佳龙, 王健. 医保药品续约政策国际经验及启示. 2024. doi: 10.12201/bmr.202407.00031

  刘明珠, 路云. 基于间断时间序列的国家药品集中带量采购协议期满品种接续工作实施效果研究——以河北省为例. 2023. doi: 10.12201/bmr.202306.00007

  郑炆苅, 邓清文, 夏宇, 刘柳, 陈英耀, 杨毅. 政策工具视角下我国医保支付体系政策文本分析. 2024. doi: 10.12201/bmr.202402.00006

  翁婷婷, 谢金平, 闫丽羽, 杨伊凡, 邵蓉. 美欧国家孤儿药认定标准的比较及启示. 2023. doi: 10.12201/bmr.202302.00010

• 序号	提交日期	编号	操作
  1	2024-04-28	bmr.202409.00048V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论